SCHEMBL4846241

SCHEMBL4846241

CCCc1ccc(F)cc1.NC(=O)CCc1ccc(F)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.54
ALDH1A1 P00352 2/20 0.54
HPGD P15428 2/20 0.53
TDP1 Q9NUW8 2/20 0.51
GAA P10253 1/20 0.51
FFAR1 O14842 1/20 0.47
SLC5A1 P13866 1/20 0.45
SLC5A2 P31639 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
AOC2 O75106 1/20 0.45
MAOA P21397 1/20 0.45
MAOB P27338 1/20 0.45
AOC3 Q16853 1/20 0.45
TAAR1 Q96RJ0 1/20 0.44
HSD11B1 P28845 1/20 0.44
POLB P06746 1/20 0.44
APEX1 P27695 1/20 0.44
HTR7 P34969 1/20 0.43
CAPN1 P07384 1/20 0.43
PLK1 P53350 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2466699 0.91 FFAR1 (0.55) LMNAALDH1A1HPGDFFAR1SLC5A1
SCHEMBL608865 0.91 ALDH1A1 (0.62) LMNAALDH1A1GAAL3MBTL1POLB
SCHEMBL27988046 0.85 MAOB (0.55) LMNAALDH1A1HPGDFFAR1SLC5A1
SCHEMBL7011662 0.84 FFAR1 (0.67) FFAR1SLC5A1SLC5A2
Bicarbonate SCHEMBL3434734 0.83 TDP1 (0.58) LMNAALDH1A1HPGDTDP1GAA
SCHEMBL658360 0.81 LMNA (0.54) LMNAHPGDFFAR1SLC5A1SLC5A2
SCHEMBL8817386 0.81 ALDH1A1 (0.51) LMNAALDH1A1HPGDL3MBTL1PLK1
SCHEMBL2170992 0.81 FFAR1 (0.53) FFAR1SLC5A1SLC5A2AOC2MAOA
SCHEMBL2170069 0.81 FFAR1 (0.46) LMNAALDH1A1HPGDTDP1FFAR1
SCHEMBL17068942 0.80 TAAR1 (0.56) LMNAALDH1A1HPGDTDP1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7462620-B2 Pyrimidinone derivatives and their use in the treatment of atherosclerosis SMITHKLINE BEECHAM, PLC (GB) 2008-12-09 US disclosed
US-20060241126-A1 Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis ELLIOTT RICHARD L 2006-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241126-A1 Pyrimidinone Derivatives and Their Use in the Treatment of Atherosclerosis PLA2G7, PLA2G1B, PLA2G4B LMNA 410/4885ALDH1A1 505/4885HPGD 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.